PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8627552-6 1996 In vitro, 6-O-demethylgalanthamine was 10- to 20-fold more potent than GAL as an inhibitor of AChE, and it demonstrated greater selectivity for inhibition of AChE vs. butyrylcholinesterase. Galantamine 71-74 acetylcholinesterase Rattus norvegicus 94-98 10399139-0 1999 Effect of the acetylcholinesterase inhibitor galanthamine on learning and memory in prolonged alcohol intake rat model of acetylcholine deficit. Galantamine 45-57 acetylcholinesterase Rattus norvegicus 14-34 10399139-2 1999 In this study, we examined the effect of the acetylcholinesterase inhibitor galanthamine in a prolonged alcohol intake model of ACh deficit in male Wistar rats. Galantamine 76-88 acetylcholinesterase Rattus norvegicus 45-65 8627552-0 1996 Pharmacological evaluation of novel Alzheimer"s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. Galantamine 113-125 acetylcholinesterase Rattus norvegicus 70-90 8627552-2 1996 Recently, another AChE inhibitor, galanthamine hydrobromide (GAL), has shown increased clinical efficacy and safety. Galantamine 34-59 acetylcholinesterase Rattus norvegicus 18-22 8627552-2 1996 Recently, another AChE inhibitor, galanthamine hydrobromide (GAL), has shown increased clinical efficacy and safety. Galantamine 61-64 acetylcholinesterase Rattus norvegicus 18-22 7901379-1 1993 The disappearance kinetics of the acetylcholinesterase inhibitor galanthamine hydrobromide from the gastrointestinal tract of male Wistar rats, 200-250 g, in-situ has been examined. Galantamine 65-90 acetylcholinesterase Rattus norvegicus 34-54 2547169-2 1989 Parameters of MEPC of the rat diaphragm with different degrees of acetylcholinesterase inhibition by galanthamine were used to estimate the lower levels of acetylcholine diffussion coefficient (0.86.10-6 cm2/s) and channel opening rate constant (21000 s-1). Galantamine 101-113 acetylcholinesterase Rattus norvegicus 66-86 1738791-2 1992 Tacrine or galanthamine, inhibitors of acetylcholinesterase, given in conjunction with scopolamine partially reversed the scopolamine-induced deficit in passive avoidance performance. Galantamine 11-23 acetylcholinesterase Rattus norvegicus 39-59 1878554-1 1991 Nerve-evoked end-plate currents were recorded intracellularly in rat diaphragm when acetylcholinesterase (AChE) was intact or in the presence of galanthamine which reduces AChE activity up to 50% or 75%. Galantamine 145-157 acetylcholinesterase Rattus norvegicus 172-176 3390582-0 1988 [Quantitative estimation of synaptic acetylcholinesterase inhibition with galanthamine using parameters of miniature endplate currents]. Galantamine 74-86 acetylcholinesterase Rattus norvegicus 37-57 3390582-3 1988 Using the model suggested, the changes in the junctional AChE activity inhibited with different concentrations of galanthamine were estimated. Galantamine 114-126 acetylcholinesterase Rattus norvegicus 57-61 2999623-0 1985 [Miniature currents of the endplates of the muscle fibers of the diaphragm of the rat after inhibition of acetylcholinesterase with galanthamine]. Galantamine 132-144 acetylcholinesterase Rattus norvegicus 106-126 2999623-1 1985 Miniature end-plate currents (MEPC) in rat diaphragm were studied with voltage-clamp technique when synaptic acetylcholinesterase (AChE) was inhibited with different concentrations of galanthamine. Galantamine 184-196 acetylcholinesterase Rattus norvegicus 109-129 2999623-1 1985 Miniature end-plate currents (MEPC) in rat diaphragm were studied with voltage-clamp technique when synaptic acetylcholinesterase (AChE) was inhibited with different concentrations of galanthamine. Galantamine 184-196 acetylcholinesterase Rattus norvegicus 131-135 33022302-3 2020 The acetylcholinesterase (AChE) inhibitor galantamine is a nAChR PAM at a low dose range. Galantamine 42-53 acetylcholinesterase Rattus norvegicus 4-24 33022302-3 2020 The acetylcholinesterase (AChE) inhibitor galantamine is a nAChR PAM at a low dose range. Galantamine 42-53 acetylcholinesterase Rattus norvegicus 26-30 28929435-9 2018 Antidotal treatment with galantamine alone (3 mg/kg) and galantamine plus atropine (10 mg/kg) has protected animals from nerve agent-induced intoxication, death, and soman-inhibited AChE up to 45% in the blood and brain. Galantamine 25-36 acetylcholinesterase Rattus norvegicus 182-186 26405825-1 2016 Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side effects. Galantamine 0-24 acetylcholinesterase Rattus norvegicus 38-58 29074413-0 2018 Galantamine attenuates N,N-dimethyl hydrazine induced neoplastic colon damage by inhibiting acetylcholinesterase and bimodal regulation of nicotinic cholinergic neurotransmission. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 92-112 29074413-13 2018 GAL by inhibiting AchE and regulating Alpha7nACh activity can improve cholinergic neurotransmission. Galantamine 0-3 acetylcholinesterase Rattus norvegicus 18-22 27829466-5 2016 Galantamine (5 mg/kg), an acetylcholinesterase inhibitor, was intraperitoneally administered as a positive control. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 26-46 23599333-3 2013 We also sought to establish whether galantamine, an acetylcholinesterase inhibitor that promotes RGC survival, can protect the retinal microvasculature and enhance blood flow in experimental glaucoma. Galantamine 36-47 acetylcholinesterase Rattus norvegicus 52-72 25529145-9 2015 The results suggest that the neuroprotective effects might be associated with lycorine and crinine-type alkaloids, whereas the acetylcholinesterase enzyme inhibitory activity could be related to galanthamine and lycorine-type alkaloids, although not based on synergistic processes. Galantamine 195-207 acetylcholinesterase Rattus norvegicus 127-147 26262991-4 2015 Galantamine lowered the n5-STZ-induced elevation in body weight, food/water intake, serum levels of glucose, fructosamine, and ALT/AST, as well as AChE in the tested organs. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 147-151 25281804-4 2014 In the present study, we aimed to investigate whether the acetylcholinesterase inhibitor galanthamine could reverse pre-cognitive prepulse inhibition (PPI) deficits and spatial learning deficits of adult rats in the Morris water maze. Galantamine 89-101 acetylcholinesterase Rattus norvegicus 58-78 25281804-8 2014 The results suggest that acetylcholinesterase inhibitors, such as galanthamine, might have the potential to improve pre-cognition in neurodevelopmental diseases by improving auditory sensory gating. Galantamine 66-78 acetylcholinesterase Rattus norvegicus 25-45 24972037-0 2014 Galantamine, an acetylcholinesterase inhibitor, reduces brain damage induced by hypoxia-ischemia in newborn rats. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 16-36 24972037-1 2014 AIM: Our aim is to elucidate whether galantamine, known as an acetylcholinesterase inhibitor, reduces brain damage induced by hypoxia-ischemia (HI). Galantamine 37-48 acetylcholinesterase Rattus norvegicus 62-82 22613079-0 2012 Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Galantamine 123-148 acetylcholinesterase Rattus norvegicus 43-63 23537526-3 2013 The aim of the present study was to evaluate the possible preventive effects of acute treatment with reversible acetylcholinesterase inhibitor galantamine against the signs of cholinergic toxic syndrome provoked by diisopropylfluorophosphate, such as hypothermia, muscular fasciculations, oral dyskinesia and decreased locomotor performance in a rat model of intoxication. Galantamine 143-154 acetylcholinesterase Rattus norvegicus 112-132 23537526-7 2013 Galantamine by itself provoked transient and relatively weak inhibition of the acetylcholinesterase staining, while it did not induce increased c-fos mRNA expression or significant behavioural signs of cholinergic toxicity. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 79-99 23888706-5 2013 The results showed that the success rate of vascular dementia model was 83.08% after six weeks; the results also showed that echinacoside and galantamine could increase the content of ACh and reduce the content of Ch extracellular of hippocampus and striatum significantly and the AChE activity increased significantly compared with that of the model group. Galantamine 142-153 acetylcholinesterase Rattus norvegicus 281-285 22359054-6 2012 The uptake of [(3)H]ALCAR by TR-BBB cells was inhibited by AChE inhibitors such as donepezil, tacrine, galantamine and rivastigmine, which IC(50) values are 45.3, 74.0, 459 and 800 muM, respectively. Galantamine 103-114 acetylcholinesterase Rattus norvegicus 59-63 22669169-0 2012 Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 16-36 22669169-2 2012 Galantamine is an acetylcholinesterase inhibitor that also acts as a positive allosteric modulator of nicotinic acetylcholine receptors. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 18-38 22359054-9 2012 Our results suggest that transport of AChE inhibitors such as donepezil and galantamine through the BBB is at least partly mediated by OCTN2 which is involved in transport of ALCAR. Galantamine 76-87 acetylcholinesterase Rattus norvegicus 38-42 21945033-5 2011 The nAChR agonist (and AChE inhibitor) galantamine induced a similar increase in ACh release (E(max): 1 muM). Galantamine 39-50 acetylcholinesterase Rattus norvegicus 23-27 21924263-10 2011 However, administration of acetylcholinesterase inhibitors, such as physostigmine and galantamine, resulted in amelioration of the hypobaric hypoxia induced deleterious effects. Galantamine 86-97 acetylcholinesterase Rattus norvegicus 27-47 21116174-1 2011 Acetylcholinesterase inhibitors (AChE-Is), galantamine, physostigmine and tacrine, enhance central levels of synaptic acetylcholine. Galantamine 43-54 acetylcholinesterase Rattus norvegicus 0-20 19446892-10 2009 Administration of AChE inhibitor (AChEI), physostigmine (PHY) and galantamine (GAL) to rats during HBH exposure resulted in amelioration of the deleterious effects induced by HBH. Galantamine 79-82 acetylcholinesterase Rattus norvegicus 18-22 21364635-5 2010 In this in vivo study, we demonstrate that systemic administration of galantamine, an acetylcholinesterase inhibitor, promotes protection of RGC soma and axons in a rat glaucoma model. Galantamine 70-81 acetylcholinesterase Rattus norvegicus 86-106 19714494-10 2010 These results suggest that nicotine as well as AChE inhibitors, donepezil and galantamine, prevent glutamate neurotoxicity through alpha4 and alpha7 nAChRs and the PI3K-Akt pathway. Galantamine 78-89 acetylcholinesterase Rattus norvegicus 47-51 18622410-6 2008 The AChE inhibitor galanthamine was also used alone or in combination with SB-271046. Galantamine 19-31 acetylcholinesterase Rattus norvegicus 4-8 19304299-1 2009 The present study was designed to assess if treatment with acetylcholinesterase inhibitor galantamine and the cholinergic precursor choline alphoscerate (alpha-glyceryl-phosphoryl-choline) alone or in association has any protective effect on brain microanatomy in spontaneously hypertensive rats (SHR) used as an animal model of vascular dementia (VaD). Galantamine 90-101 acetylcholinesterase Rattus norvegicus 59-79 19252271-2 2009 Donepezil, galantamine and tacrine are acetylcholinesterase inhibitors used for the treatment of Alzheimer"s disease, and were believed to be symptomatic drugs whose therapeutic effects are achieved by slowing the hydrolysis of acetylcholine at synaptic termini. Galantamine 11-22 acetylcholinesterase Rattus norvegicus 39-59 19021024-3 2008 The sensitivity of manipulation of cholinergic system on VAChT was assessed in rats treated for four weeks with the acetylcholinesterase (AChE) inhibitor galantamine (3 mg/Kg/day). Galantamine 154-165 acetylcholinesterase Rattus norvegicus 116-136 19021024-3 2008 The sensitivity of manipulation of cholinergic system on VAChT was assessed in rats treated for four weeks with the acetylcholinesterase (AChE) inhibitor galantamine (3 mg/Kg/day). Galantamine 154-165 acetylcholinesterase Rattus norvegicus 138-142 16925890-3 2007 By analogy to the acetylcholinesterase inhibitor, galantamine (0.0025-0.63 mg/kg s.c.), the selective and high efficacy D1 receptor agonist, SKF 82958, dose-dependently (0.0025-0.63), robustly and potently enhanced extracellular levels of acetylcholine (ACh) in the frontal cortex and hippocampus of freely moving rats. Galantamine 50-61 acetylcholinesterase Rattus norvegicus 18-38 17692343-7 2007 Moreover, suboptimal doses of VRX-03011 and the acetylcholinesterase inhibitor galanthamine combined to enhance memory. Galantamine 79-91 acetylcholinesterase Rattus norvegicus 48-68 17125927-5 2007 followed by GAL administration showed higher AChE inhibition in comparison with single GAL administration. Galantamine 12-15 acetylcholinesterase Rattus norvegicus 45-49 17125927-1 2007 Changes of acetylcholinesterase (AChE) activities in the hypophysis and brain (frontal cortex, hippocampus, medial septum and basal ganglia), and butyrylcholinesterase in plasma and liver following galanthamine (GAL) administration were studied in rats pretreated with L-carnitine (CAR). Galantamine 198-210 acetylcholinesterase Rattus norvegicus 11-31 17125927-8 2007 Thus, pretreatment with CAR enhanced AChE inhibition in some brain parts of the rat following GAL administration. Galantamine 94-97 acetylcholinesterase Rattus norvegicus 37-41 15951032-8 2005 Galantamine post-treatment also affected NMDA-induced changes in AChE and choline-acetyltransferase activities. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 65-69 16880719-1 2006 Donepezil, galanthamine, and tacrine are therapeutic acetylcholinesterase (AChE) inhibitors used for the treatment of Alzheimer"s disease. Galantamine 11-23 acetylcholinesterase Rattus norvegicus 53-73 16880719-1 2006 Donepezil, galanthamine, and tacrine are therapeutic acetylcholinesterase (AChE) inhibitors used for the treatment of Alzheimer"s disease. Galantamine 11-23 acetylcholinesterase Rattus norvegicus 75-79 16601783-3 2005 The aim of this study was to evaluate the influence of pretreatment with CAR on AChE inhibition caused by GAL in selected brain parts in rat (basal ganglia, septum, frontal cortex, hippocampus) and in hypophysis, which does not lay beyond the blood-brain-barrier. Galantamine 106-109 acetylcholinesterase Rattus norvegicus 80-84 16248990-0 2005 Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors. Galantamine 52-63 acetylcholinesterase Rattus norvegicus 98-102 17159811-0 2006 Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Galantamine 10-21 acetylcholinesterase Rattus norvegicus 25-45 15986464-1 2005 The goal of the current study was to develop an intranasal (IN) formulation of the acetylcholinesterase inhibitor galantamine, an important therapeutic for treating Alzheimer"s disease. Galantamine 114-125 acetylcholinesterase Rattus norvegicus 83-103 15694923-0 2005 Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Galantamine 54-65 acetylcholinesterase Rattus norvegicus 17-37 15823582-4 2005 We also demonstrated that galantamine, an acetylcholinesterase inhibitor with allosteric nAChR-potentiating ligand properties, prevented glutamate-induced motor neuronal death. Galantamine 26-37 acetylcholinesterase Rattus norvegicus 42-62 15694923-1 2005 Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer"s disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR). Galantamine 0-11 acetylcholinesterase Rattus norvegicus 29-49 15694923-1 2005 Galantamine is a rather weak acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer"s disease, with possible additional allosteric potentiating effects at the nicotinic ACh receptor (nAChR). Galantamine 0-11 acetylcholinesterase Rattus norvegicus 51-55 15694923-2 2005 Earlier data from in vitro biochemical tests suggest that donepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE. Galantamine 104-115 acetylcholinesterase Rattus norvegicus 130-134 15694923-3 2005 In this study, both brain levels and Ki values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous application were determined. Galantamine 85-96 acetylcholinesterase Rattus norvegicus 51-55 15694923-7 2005 Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3 microg/g in rats, 8.3 and 0.65 microg/g for mice, and 19.1 and 1.3 microg/g in rabbits. Galantamine 39-50 acetylcholinesterase Rattus norvegicus 19-23 15694923-8 2005 The data also suggest that for a similar degree of brain AChE inhibition, 3-15 times higher galantamine than donepezil doses are needed. Galantamine 92-103 acetylcholinesterase Rattus norvegicus 57-61 12493597-1 2003 Galantamine is an acetylcholinesterase inhibitor in Alzheimer"s disease therapy. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 18-38 15496314-1 2004 Galantamine, a mild acetylcholinesterase inhibitor and an allosteric ligand of nicotinic receptors, enhanced in a concentration-dependent manner the amplitude of purinergic twitch contractions of the electrically stimulated rat vas deferens (0.2 Hz, 1 ms, 60 V). Galantamine 0-11 acetylcholinesterase Rattus norvegicus 20-40 15496314-2 2004 Other acetylcholinesterase inhibitors also increased the twitches, showing a hierarchy of potencies of galantamine>physostigmine>tacrine>rivastigmine=donepezil. Galantamine 103-114 acetylcholinesterase Rattus norvegicus 6-26 15322258-8 2004 In addition, galantamine, which is both an inhibitor of AChE and an allosteric potentiator of nAChRs, had similar effects. Galantamine 13-24 acetylcholinesterase Rattus norvegicus 56-60 15245794-5 2004 Galantamine, a mild acetylcholinesterase (AChE) blocker and nicotinic receptor modulator, given 30 min before and during OGD plus re-oxygenation (1, 2 and 3 h) significantly reduced LDH release by around 50%. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 20-40 15245794-5 2004 Galantamine, a mild acetylcholinesterase (AChE) blocker and nicotinic receptor modulator, given 30 min before and during OGD plus re-oxygenation (1, 2 and 3 h) significantly reduced LDH release by around 50%. Galantamine 0-11 acetylcholinesterase Rattus norvegicus 42-46 12734391-5 2003 Among AChE inhibitors examined, donepezil and certain AChE inhibitors such as tacrine and galanthamine showed potent neuroprotective action, although physostigmine did not affect glutamate neurotoxicity. Galantamine 90-102 acetylcholinesterase Rattus norvegicus 6-10 12734391-5 2003 Among AChE inhibitors examined, donepezil and certain AChE inhibitors such as tacrine and galanthamine showed potent neuroprotective action, although physostigmine did not affect glutamate neurotoxicity. Galantamine 90-102 acetylcholinesterase Rattus norvegicus 54-58 14769831-1 2004 Galantamine, a drug for treatment of Alzheimer"s disease, is a novel cholinergic agent with a dual mode of action that inhibits acetylcholinesterase and allosterically modulates nicotinic cholinergic receptors (nAChRs). Galantamine 0-11 acetylcholinesterase Rattus norvegicus 128-148 11330337-8 2001 Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent. Galantamine 152-164 acetylcholinesterase Rattus norvegicus 51-71